Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking

por Turaj, Anna H., Cox, Kerry L., Penfold, Christine A., French, Ruth R., Mockridge, C. Ian, Willoughby, Jane E., Tutt, Alison L., Griffiths, Jordana, Johnson, Peter W. M., Glennie, Martin J., Levy, Ronald, Cragg, Mark S., Lim, Sean H.
Publicado 2018

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering

por Heckel, Franziska, Turaj, Anna H., Fisher, Hayden, Chan, H. T. Claude, Marshall, Michael J. E., Dadas, Osman, Penfold, Christine A., Inzhelevskaya, Tatyana, Mockridge, C. Ian, Alvarado, Diego, Tews, Ivo, Keler, Tibor, Beers, Stephen A., Cragg, Mark S., Lim, Sean H.
Publicado 2022

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments

por Moreno-Vicente, Julia, Willoughby, Jane E, Taylor, Martin C, Booth, Steven G, English, Vikki L, Williams, Emily L, Penfold, Christine A, Mockridge, C Ian, Inzhelevskaya, Tatyana, Kim, Jinny, Chan, H T Claude, Cragg, Mark S, Gray, Juliet C, Beers, Stephen A
Publicado 2022

Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity

por Yu, Xiaojie, Chan, H.T. Claude, Fisher, Hayden, Penfold, Christine A., Kim, Jinny, Inzhelevskaya, Tatyana, Mockridge, C. Ian, French, Ruth R., Duriez, Patrick J., Douglas, Leon R., English, Vikki, Verbeek, J. Sjef, White, Ann L., Tews, Ivo, Glennie, Martin J., Cragg, Mark S.
Publicado 2020

TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity

por Yu, Xiaojie, James, Sonya, Felce, James H., Kellermayer, Blanka, Johnston, David A., Chan, H. T. Claude, Penfold, Christine A., Kim, Jinny, Inzhelevskaya, Tatyana, Mockridge, C. Ian, Watanabe, Yasunori, Crispin, Max, French, Ruth R., Duriez, Patrick J., Douglas, Leon R., Glennie, Martin J., Cragg, Mark S.
Publicado 2021

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies

por Yu, Xiaojie, Chan, H.T. Claude, Orr, Christian M., Dadas, Osman, Booth, Steven G., Dahal, Lekh N., Penfold, Christine A., O'Brien, Lyn, Mockridge, C. Ian, French, Ruth R., Duriez, Patrick, Douglas, Leon R., Pearson, Arwen R., Cragg, Mark S., Tews, Ivo, Glennie, Martin J., White, Ann L.
Publicado 2018

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms

por Simpson, Alexander P., Roghanian, Ali, Oldham, Robert J., Chan, H.T. Claude, Penfold, Christine A., Kim, Hyung J., Inzhelevskaya, Tatyana, Mockridge, C. Ian, Cox, Kerry L., Bogdanov, Yury D., James, Sonya, Tutt, Alison L., Rycroft, Daniel, Morley, Peter, Dahal, Lekh N., Teige, Ingrid, Frendeus, Björn, Beers, Stephen A., Cragg, Mark S.
Publicado 2022

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

por White, Ann L., Chan, H.T. Claude, French, Ruth R., Willoughby, Jane, Mockridge, C. Ian, Roghanian, Ali, Penfold, Christine A., Booth, Steven G., Dodhy, Ali, Polak, Marta E., Potter, Elizabeth A., Ardern-Jones, Michael R., Verbeek, J. Sjef, Johnson, Peter W.M., Al-Shamkhani, Aymen, Cragg, Mark S., Beers, Stephen A., Glennie, Martin J.
Publicado 2015